Commercial antibodies and their validation.
Commercial antibodies and their validation.
复制标题
DOI：
10.12688/f1000research.4966.2
复制
发表时间：
2014
期刊：
影响因子：
--
通讯作者：
Voskuil J
中科院分区：
文献类型：
--
作者：
Voskuil J
尽管研究抗体的业务有了令人印象深刻的增长，但人们对商业抗体普遍缺乏信任。各种各样的问题，每个问题都可能导致一种抗体失效，巩固了科学家们忍受的挫折感。大量的资金被浪费在购买和尝试一个又一个失败的抗体上，而没有意识到产品带来的所有陷阱：抗体可能被灭活，生物材料和检测本身都可能存在缺陷，出现在许多不同目录中的单一抗体可以被认为是一组不同的产品，抗体类型选择不当，稀释错误，以及缺乏适当的验证，所有这些都可能危及预期的实验。由科研论文认可的抗体并不总是符合科学家的要求，要么是因为有缺陷的规格，要么是因为批次之间的差异。抗体可以从以前的批次获得的质量控制数据中找到，这些批次不再代表正在销售的批次。此外，人们不能假设每种抗体都适用于每一种应用。最有可能成功的是尝试一种已经被确认在所需平台上正确发挥作用的抗体。
Despite an impressive growth in the business of research antibodies a general lack of trust in commercial antibodies remains in place. A variety of issues, each one potentially causing an antibody to fail, underpin the frustrations that scientists endure. Lots of money goes to waste in buying and trying one failing antibody after the other without realizing all the pitfalls that come with the product: Antibodies can get inactivated, both the biological material and the assay itself can potentially be flawed, a single antibody featuring in many different catalogues can be deemed as a set of different products, and a bad choice of antibody type, wrong dilutions, and lack of proper validation can all jeopardize the intended experiments. Antibodies endorsed by scientific research papers do not always meet the scientist’s requirements either due to flawed specifications, or due to batch-to-batch variations. Antibodies can be found with Quality Control data obtained from previous batches that no longer represent the batch on sale. In addition, one cannot assume that every antibody is fit for every application. The best chance of success is to try an antibody that already was confirmed to perform correctly in the required platform.